Inclusion Criteria:

          1. Males or females, age 18 years or older

          2. Diagnosis of multiple myeloma (MM) and documentation of treatment

               -  ARM 1: Must have prior exposure to an immunomodulatory drug (IMiD) and proteasome
                  inhibitor (PI) and have had 2 prior regimens/lines of therapy; but there is no
                  maximum number of prior regimens, and prior autologous bone marrow transplant is
                  acceptable if > 12 weeks from transplantation; patients may have received prior
                  carfilzomib (sensitive, relapsed and refractory [having progressed while
                  receiving carfilzomib or within 60 days of stopping carfilzomib] are all
                  eligible), but must be > 4 weeks from last dosing of carfilzomib

               -  ARM 2: Must have had at least 1 but no more than 3 prior lines of anti-myeloma
                  therapy; may be refractory to lenalidomide but sensitive to carfilzomib; prior
                  exposure to carfilzomib is allowed but may not be refractory to carfilzomib;
                  subjects must be >= 8 weeks from last carfilzomib therapy

               -  A line of therapy is defined as a course of therapy that is not interrupted by
                  progressive disease; for example, induction therapy, autologous stem cell
                  transplantation, and maintenance therapy without intervening progressive disease
                  is one line of therapy

          3. Confirmed evidence of relapse/disease progression from immediately prior MM therapy or
             relapsed and refractory to the immediately prior treatment; relapsed and refractory
             disease is defined as those who are non-responsive (< minimal response) on salvage
             therapy or experience disease progression within 60 days of last therapy in patients
             who have achieved an MR or better to previous therapy; relapsed disease is defined as
             previously treated myeloma that progresses and requires the initiation of salvage
             therapy but does not meet IMWG criteria for relapsed and refractory

          4. Patients may have received prior carfilzomib (sensitive, relapsed and refractory all
             eligible); response and duration of prior carfilzomib therapy must be known

          5. Patients must have measurable disease defined as at least one of the following:

               -  Serum M-protein >= 0.5 g/dl (>= 5 g/l)

               -  Urine M-protein >= 200 mg/24 hours (h)

               -  Serum free light chain (FLC) assay: involved FLC level >= 10 mg/dl (>= 100 mg/l)
                  and an abnormal serum free light chain ratio (< 0.26 or > 1.65)

               -  Quantitative immunoglobulin > 500 mg/dL, only for immunoglobulin (Ig)A and (Ig)D
                  myeloma when the protein electrophoresis under-represents disease burden

               -  Biopsy proven plasmacytoma > 1x1 cm (should be measured within 28 days prior to
                  initial investigational agent dosing)

          6. Subject has an Eastern Cooperative Oncology Group (ECOG) =< 2 performance status OR
             Karnofsky >= 60% performance status

          7. Females of childbearing potential (FCBP)

               -  A female of childbearing potential is a sexually mature woman who: 1) has not
                  undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally
                  postmenopausal for at least 24 consecutive months

               -  Females of childbearing potential must have a negative serum beta-human chorionic
                  gonadotropin (beta-hCG) pregnancy test with a sensitivity of at least 50
                  milli-international units per milliliter(mIU/mL), within 10-14 days of study
                  start (during screening)

               -  FCBP must also agree to ongoing pregnancy testing. Pregnancy testing is not
                  required for post-menopausal or surgically sterilized women

               -  Females must agree to avoid pregnancy during the study and must agree to use a
                  medically acceptable method of birth control as determined by the study doctor
                  while participating in the study and for at least 5 months after the last dose of
                  study medication

          8. Men must agree to use contraception (i.e. a latex condom) during sexual contact with a
             FCBP even if they have had a successful vasectomy and agree to not donate sperm for 5
             months after last study therapy (SAR650984, lenalidomide and carfilzomib).

          9. Voluntary written informed consent before performance of any study-related procedure
             not part of routine medical care with the understanding that consent may be withdrawn
             by the subject at any time without prejudice to future medical care

         10. Ability to understand the purpose and risks of the study and provide signed and dated
             informed consent and authorization to use protected health information (in accordance
             with national and local subject privacy regulations)

         11. For patients with platelets > 100,000 cells/ul (100x10^9/L) able to take aspirin daily
             as prophylactic anticoagulation therapy for ARM 2 (patients intolerant to aspirin may
             use warfarin, low-molecular-weight heparin or equivalent anti-platelet therapy)

         12. Inclusion Clinical Laboratories Criteria. The following laboratory results must be
             met:

               -  Absolute neutrophil count (ANC) > 1,000 cells/dL (1.0 x 10e9/L) (growth factor
                  cannot be used within the previous 7 days)

               -  Hemoglobin >= 8.0 g/dl (without transfusion within the previous 7 days)

               -  Platelet count > 75,000 cells/dL (75 x 10e9/L)

               -  Creatinine clearance >= 30 mL/min (Cockcroft-Gault equation)

               -  Serum glutamic oxaloacetic transaminase (SGOT)/aspartate aminotransferase (AST)
                  or serum glutamate pyruvate transaminase (SGPT)/alanine aminotransferase (ALT) <
                  2.5 x upper limit of normal (ULN)

               -  Total bilirubin =< 1.5 x ULN

               -  Serum calcium (corrected for albumin) level at or below the ULN range (treatment
                  of hypercalcemia is allowed and subject may enroll if hypercalcemia returns to
                  normal with standard treatment) prior to study therapy initiation

               -  Left ventricular ejection fraction (LVEF) >= 40% (by echocardiogram or multigated
                  acquisition scan (MUGA) testing)

               -  Fasting glucose under control (< 150 mg/dL [8.3 mmol/L])

        Exclusion Criteria:

        Patients who have met all the inclusion criteria listed above will be screened for the
        following exclusion criteria:

          1. Diagnosed or treated for another malignancy within 3 years of enrollment, with the
             exception of complete resection of basal cell carcinoma or squamous cell carcinoma of
             the skin, an in situ malignancy, low-risk prostate cancer after curative therapy or
             complete resection of other advanced malignancy with the expectation that the patient
             has received curative therapy

          2. Patient has received other investigational drugs with 21 days before enrollment (or
             must be > than four half-lives of the experimental agent); no prior SAR650984
             anti-CD38 antibody therapy allowed

          3. History of significant cardiovascular disease unless the disease is well-controlled or
             history of myocardial infarction in the past 6 months; significant cardiac diseases
             includes second/third degree heart block; significant conduction abnormalities,
             significant ischemic heart disease; poorly controlled hypertension; congestive heart
             failure of New York Heart Association (NYHA) class II or worse (slight limitation of
             physical activity; comfortable at rest, but ordinary physical activity results in
             fatigue, palpitation, or dyspnea) and inability to tolerate intravenous hydration
             necessary for study therapy administration

          4. Prior autologous or allogeneic peripheral stem cell transplant within 12 weeks of the
             first dose of study treatment

          5. Daily requirement for corticosteroids (> 10 mg prednisone once daily (QD) or
             equivalent)

          6. Patients with evidence of significant mucosal or internal bleeding

          7. Prior radiation therapy or chemotherapy within 2 weeks or major surgical procedure
             within 4 weeks of the first dose of study treatment

          8. Known active infection requiring parenteral or oral anti-infective treatment, once a
             patient has completed antibiotics and symptoms of infection have resolved to < grade
             2, they are then considered eligible from an infection standpoint

          9. Serious psychiatric illness, active alcoholism, or drug addiction that may hinder or
             confuse follow-up evaluation

         10. Any medical conditions that, in the Investigator's opinion, would impose excessive
             risk to the patient; examples of such conditions include any pre-existing kidney
             disease (acute or chronic, unless renal insufficiency is felt to be secondary to MM),
             hypertension, active seizure disorder or pulmonary diseases that would impose
             excessive risk to the patient

         11. Patient has hypersensitivity to boron, mannitol sucrose, histidine (as base and
             hydrochloride salt) and polysorbate 80 or any of the components of study therapy
             including required prophylactic medications

         12. Known human immunodeficiency virus (HIV) seropositivity or active hepatitis B or C
             viral infection

         13. Neuropathy >= grade 3 or painful neuropathy >= grade 2 (National Cancer Institute
             Common Terminology Criteria for Adverse Events [NCI CTCAE] version [v]4.03)

         14. Gastro-intestinal abnormalities, including bowel obstruction, inability to take oral
             medication, requirement for intravenous (IV) alimentation, active peptic ulcer or
             prior surgical procedures or bowel resection affecting absorption